SUMMARY
# Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-Tauopathy
## Background and Rationale
This validation study addresses a critical gap in 4R-tauopathy therapeutic development by directly comparing three distinct anti-tau strategies: extracellular antibody-mediated clearance, intracellular mRNA targeting via antisense oligonucleotides, and gene therapy approaches. The 4R-tau isoform is particularly relevant as it predominates in progressive supranuclear palsy (PSP) and corticob
METHODOLOGY NOTES
**Phase 1: Cell Culture Establishment and Tau Overexpression (Days 1-7)**
Establish HEK293T and SH-SY5Y neuroblastoma cell lines in 24-well plates (n=12 wells per condition). Transfect cells with 4R-tau (MAPT 2N4R isoform) expression plasmid using Lipofectamine 3000. Confirm tau overexpression via Western blot using anti-tau antibodies (Tau5, AT8 for phosphorylated tau). Maintain cells in DMEM + 10% FBS with G418 selection (400 μg/ml) for stable transfectants.
**Phase 2: Treatment Intervention Setup (Days 8-10)**
Randomize cells into four treatment groups: (1) Anti-tau monoclonal antibody (10 μg/ml, targeting extracellular tau), (2) Antisense oligonucleotide against MAPT mRNA (50 nM, MOE-modified gapmer design), (3) CRISPR-dCas9 gene therapy approach for tau knockdown (multiplicity of infection = 5), (4) Vehicle control (PBS + lipofectamine). Prepare fresh treatments every 48 hours.
**Phase 3: Longitudinal Monitoring and Sample Collection (Days 11-25)**
Collect samples at 24h, 72h